MedTrace Logo

Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer

NCT01935934 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2025-10-01

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well cabozantinib s-malate works in treating patients with endometrial cancer that has come back (recurrent) or has spread to other places in the body (metastatic). Cabozantinib s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Conditions

  • Endometrial Adenosquamous Carcinoma
  • Endometrial Clear Cell Adenocarcinoma
  • Endometrial Mixed Cell Adenocarcinoma
  • Endometrial Serous Adenocarcinoma
  • Metastatic Endometrioid Adenocarcinoma
  • Recurrent Malignant Uterine Corpus Neoplasm
  • Stage IV Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
  • Stage IVA Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
  • Stage IVB Uterine Corpus Carcinoma or Carcinosarcoma by AJCC v7 Stage
  • Uterine Corpus Carcinosarcoma

Interventions

DRUG

Cabozantinib S-malate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Neesha Dhani · University Health Network-Princess Margaret Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-08
Primary Completion
2019-09-12
Completion
2024-10-24

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01935934 on ClinicalTrials.gov